BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that two GencaroTM (bucindolol hydrochloride) abstracts have been accepted for poster sessions at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009 in Orlando, Florida. The abstracts present data from the pivotal Phase 3 BEST trial of Gencaro in patients with advanced chronic heart failure:
